Table 5. Anti-proliferative Activity of Synthesized Pyridine-Based 1,2,4-Triazolo-Tethered Indole Conjugates (14a–q) against Different Human Cancer Cell Lines.
| IC50 against the selected cell
lines |
|||||||
|---|---|---|---|---|---|---|---|
| entry | compd | CACO2 | DLD1 | A172 | A549 | TERA-1 | HT-29 |
| 1 | 14a | 3.9 ± 0.6 | 7 ± 1.3 | 9 ± 0.8 | 6.7 ± 1.2 | 4.3 ± 0.4 | 1.0 ± 0.4 |
| 2 | 14b | >30 | >30 | >30 | >30 | >30 | >30 |
| 3 | 14c | >30 | >30 | >30 | >30 | >30 | >30 |
| 4 | 14d | 25 ± 1.0 | 21.8 ± 1.2 | 23.3 ± 0.7 | 18.7 ± 1.6 | >30 | >30 |
| 5 | 14e | 17.8 ± 1.2 | 16.5 ± 0.8 | 20.3 ± 0.8 | 13.5 ± 1.6 | >30 | >30 |
| 6 | 14f | >30 | >30 | >30 | >30 | >30 | >30 |
| 7 | 14g | 10.5 ± 0.5 | 15.3 ± 1.2 | 14.7 ± 0.9 | 14.5 ± 0.3 | 24.6 ± 1.0 | 12.2 ± 1.6 |
| 8 | 14h | >30 | >30 | >30 | >30 | >30 | >30 |
| 9 | 14i | >30 | >30 | >30 | 4.0 ± 0.7 | >30 | >30 |
| 10 | 14] | >30 | >30 | 16.9 ± 1.1 | >30 | >30 | >30 |
| 11 | 14k | 10.3 ± 0.4 | 10.6 ± 1.1 | >30 | 8.09 ± 0.2 | >30 | 5.8 ± 1.2 |
| 12 | 14l | 13.5 ± 0.9 | 11 ± 1.5 | >30 | >30 | >30 | 7.3 ± 0.8 |
| 13 | 14m | >30 | 19 ± 0.3 | 26.8 ± 1.6 | >30 | >30 | >30 |
| 14 | 14n | 9.1 ± 0.8 | 7 ± 1.2 | 9.5 ± 1.4 | 5.3 ± 0.2 | 10.5 ± 0.5 | 2.4 ± 0.6 |
| 15 | 14o | >30 | >30 | >30 | >30 | >30 | >30 |
| 16 | 14p | >30 | 25.8 ± 1.6 | 8.1 ± 0.7 | 13.9 ± 1.2 | 10.7 ± 1.4 | >30 |
| 17 | 14q | 15.5 ± 1.1 | 9.3 ± 1.4 | 26.8 ± 1.6 | 25.1 ± 0.8 | 19.4 ± 0.5 | 3.6 ± 0.3 |